(NASDAQ: KROS) Keros Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.37%.
Keros Therapeutics's earnings in 2026 is $87,014,000.On average, 11 Wall Street analysts forecast KROS's earnings for 2026 to be -$107,448,724, with the lowest KROS earnings forecast at -$174,295,105, and the highest KROS earnings forecast at -$75,774,479. On average, 10 Wall Street analysts forecast KROS's earnings for 2027 to be -$115,694,597, with the lowest KROS earnings forecast at -$242,312,707, and the highest KROS earnings forecast at -$53,000,729.
In 2028, KROS is forecast to generate -$55,676,398 in earnings, with the lowest earnings forecast at -$101,446,707 and the highest earnings forecast at -$17,804,932.